Latest Fisher & Paykel Healthcare (ASX:FPH) News

Cannabis and psychedelics delivered the week’s biggest winner, while a cluster of smaller caps slid on fresh losses, leadership change, and near-term uncertainty. Investors kept paying up for FDA clearances and reimbursement wins, but punished businesses where early pops quickly disappeared.

Fisher & Paykel Healthcare has raised its full-year revenue and profit forecasts for FY26, buoyed by strong hospital product growth and favourable exchange rates, while navigating the complexities of a recent US Supreme Court tariff ruling.

Fisher & Paykel Healthcare has updated its dividend announcement to include the Australian Dollar equivalent, providing clearer insight for investors ahead of the mid-December payment.

Fisher & Paykel Healthcare reported a robust 14% revenue increase and a 39% jump in net profit for the first half of fiscal 2026, driven by strong clinical adoption and product innovation.

Fisher & Paykel Healthcare has issued strong first half FY26 guidance, forecasting significant revenue and profit growth while navigating new US tariffs. Meanwhile, director Pip Greenwood announces her retirement after eight years on the board.

Fisher & Paykel Healthcare has announced an ordinary dividend of NZD 0.28235294 per share for the six months ending March 31, 2025, payable on July 4. The dividend is unfranked and includes a supplementary component, with a 15% withholding tax applied.

Fisher & Paykel Healthcare has reported a record full-year revenue of NZ$2.02 billion for FY2025, alongside a 43% increase in underlying net profit after tax. The company also raised its dividend, reflecting strong operational performance and strategic investments.

Fisher & Paykel Healthcare anticipates increased costs from newly imposed US tariffs on imports from Mexico and China, potentially delaying its gross margin recovery timeline but expects no immediate profit impact for FY2025.